These data collectively support the hypothesis that ARID1B activity is functionally amplified specifically in ARID1A‐mutant breast cancers, highlighting a dominant oncogenic role of ARID1B‐dependent transcriptional programs in this context. This evidence concerns the gene ARID1B and breast carcinoma.